OMDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Omada Health Inc (OMDA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive analyst sentiment, and promising developments in its GLP-1 Care Track program position it well for future growth. While there are some concerns regarding declining net income and EPS, these are outweighed by the company's robust growth potential and diversified platform.
The stock's MACD is positive at 0.257, indicating bullish momentum, and RSI is neutral at 65.976. The price is currently trading near a key resistance level (R1: 14.73), suggesting potential for further upside if this level is breached. Moving averages are converging, indicating a potential trend reversal or continuation.
Analysts maintain an Outperform rating with price targets ranging from $15 to $30, indicating confidence in the company's growth potential.
A recent study highlighted the effectiveness of Omada's GLP-1 Care Track program, showcasing its innovative healthcare solutions.
Revenue growth of 58.08% YoY in Q4 2025 demonstrates strong business momentum.
Net income and EPS have significantly declined YoY, which could raise concerns about profitability.
Broader valuation pressure in the Healthcare Information Technology sector may weigh on the stock.
In Q4 2025, Omada Health reported a 58.08% YoY increase in revenue, reaching $75.85M. However, net income dropped by -162.53% YoY to $5.16M, and EPS declined by -160.00% YoY to 0.09. Gross margin improved to 70.75%, up 5.64% YoY, indicating operational efficiency.
Analysts are broadly positive on the stock, with multiple Outperform and Overweight ratings. Recent price target adjustments reflect a cautious but optimistic outlook, with targets ranging from $15 to $30. Analysts highlight Omada's strong growth momentum, diversified platform, and potential for upside via execution.
